相似文献
1
Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease.
Gut. 1980 Dec;21(12):1030-4. doi: 10.1136/gut.21.12.1030.
2
Humoral immune system in inflammatory bowel disease: I. Complement levels.
Gut. 1977 Sep;18(9):749-53. doi: 10.1136/gut.18.9.749.
3
Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
Clin Exp Immunol. 1979 Jun;36(3):408-14.
4
Control of complement activation in membranous and membranoproliferative glomerulonephritis.
Kidney Int. 1980 Apr;17(4):535-44. doi: 10.1038/ki.1980.62.
5
Control of serum C3 levels by beta 1H and C3b inactivator.
J Lab Clin Med. 1980 Jun;95(6):905-17.
6
Evidence for glomerular modulation of complement activation.
J Clin Lab Immunol. 1979 Apr;2(1):9-13.
7
Complement alterations in inflammatory bowel disease.
Gastroenterology. 1979 Jun;76(6):1374-9.
8
High normal serum levels of C3 and C1 inhibitor, two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis.
Dig Dis Sci. 2003 Jun;48(6):1186-92. doi: 10.1023/a:1023793502456.
9
Serum C3 and C4 complement components in ulcerative colitis and Crohn's disease.
Digestion. 1975;13(1-2):100-3. doi: 10.1159/000197698.
10
Acute-phase reactant proteins and complement components and inhibitors in patients with ovarian cancer.
Gynecol Oncol. 1981 Jun;11(3):288-98. doi: 10.1016/0090-8258(81)90042-1.
引用本文的文献
1
Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis.
Front Pharmacol. 2022 Jun 13;13:905133. doi: 10.3389/fphar.2022.905133. eCollection 2022.
2
Low CFB expression is independently associated with poor overall and disease-free survival in patients with lung adenocarcinoma.
Oncol Lett. 2021 Jun;21(6):478. doi: 10.3892/ol.2021.12739. Epub 2021 Apr 19.
3
Autoantibodies Against C3b-Functional Consequences and Disease Relevance.
Front Immunol. 2019 Jan 29;10:64. doi: 10.3389/fimmu.2019.00064. eCollection 2019.
4
A cross-ethnic survey of CFB and SLC44A4, Indian ulcerative colitis GWAS hits, underscores their potential role in disease susceptibility.
Eur J Hum Genet. 2016 Jan;25(1):111-122. doi: 10.1038/ejhg.2016.131. Epub 2016 Oct 19.
5
Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.
J Biol Chem. 2015 Oct 16;290(42):25343-55. doi: 10.1074/jbc.M115.647008. Epub 2015 Aug 5.
6
Subnormal activation of phagocytes by complement in chronic inflammatory bowel disease? Neutrophil chemotaxis to complement split product C5a.
Gut. 1984 Jul;25(7):737-42. doi: 10.1136/gut.25.7.737.
7
Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement.
Gut. 1985 Feb;26(2):151-7. doi: 10.1136/gut.26.2.151.
8
Abnormal metabolism of arachidonic acid in chronic inflammatory bowel disease: enhanced release of leucotriene B4 from activated neutrophils.
Gut. 1987 Feb;28(2):181-5. doi: 10.1136/gut.28.2.181.
9
The immunology of inflammatory bowel disease.
Springer Semin Immunopathol. 1990;12(2-3):251-68. doi: 10.1007/BF00197510.
本文引用的文献
1
Cortisone in ulcerative colitis; final report on a therapeutic trial.
Br Med J. 1955 Oct 29;2(4947):1041-8. doi: 10.1136/bmj.2.4947.1041.
2
Positive epinephrine skin test for "circulating endotoxin" in inflammatory disease of the intestine.
Am J Clin Pathol. 1965 Dec;44(6):642-7. doi: 10.1093/ajcp/44.6.642.
3
Decreased properdin activity in acute glomerulonephritis.
Int Arch Allergy Appl Immunol. 1969;36(6):592-8. doi: 10.1159/000230780.
4
Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus.
Clin Exp Immunol. 1969 Feb;4(2):191-202.
5
Short-term course and prognosis of Crohn's disease.
Gut. 1974 Jun;15(6):435-43. doi: 10.1136/gut.15.6.435.
6
Proceedings: Serum complement components C3 and C4 in inflammatory bowel disease.
Gut. 1974 Oct;15(10):835.
7
Circulating immune complexes in inflammatory bowel disease.
Clin Exp Immunol. 1973 Jun;14(2):219-26.
8
Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components.
J Exp Med. 1968 Nov 1;128(5):1049-57. doi: 10.1084/jem.128.5.1049.
9
Evidence of cytotoxicity in ulcerative colitis from immunofluorescent staining of the rectal mucosa.
Lancet. 1974 May 25;1(7865):1014-7. doi: 10.1016/s0140-6736(74)90416-4.
10
Evidence for complement-binding immune complexes in adult coeliac disease, Crohn's disease, and ulcerative colitis.
Lancet. 1973 Feb 24;1(7800):402-3. doi: 10.1016/s0140-6736(73)90254-7.
Zotero 插件